| Dr Matthew Scott Hamm, MD, MPH | |
|
16205 N Pennsylvania Ave, Edmond, OK 73013-7325 | |
| (405) 705-5700 | |
| Not Available |
| Full Name | Dr Matthew Scott Hamm |
|---|---|
| Gender | Male |
| Speciality | Preventive Medicine |
| Experience | 11 Years |
| Location | 16205 N Pennsylvania Ave, Edmond, Oklahoma |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083058168 | NPI | - | NPPES |
| Entity Name | Primamed Physicians, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164494068 PECOS PAC ID: 9234027897 Enrollment ID: O20040316000446 |
News Archive
An unexpected finding by an international team of scientists based at The University of Manchester and National Institutes of Health in America has shed new light on how immune cells are programmed to either repair or protect the body.
Drs. Andrew Goldstein, Owen Witte, and Tanya Stoyanova and their colleagues from UCLA's Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research have found that prostate cancer can develop in one type of stem cell, then evolve to be maintained by a stem cell that looks very different, making prostate cancer stem cells a "moving target" for treatments. The breakthrough discovery connects directly to the development of future therapeutics that target cancer and was published online ahead of print in the Proceedings of the National Academy of Sciences.
Frequent soccer ball heading is a common and under recognized cause of concussion symptoms, according to a study of amateur players led by Albert Einstein College of Medicine researchers.
Starting statin therapy as young as age 8 safely and effectively delays the early artery damage caused by familial hypercholesterolemia (FH), according to a Dutch study reported in the Aug.7th print issue of Circulation: Journal of the American Heart Association.
MultiCell Technologies, Inc. and its majority owned subsidiary, Xenogenics Corporation, are pleased to announce the acquisition of the Ideal™ BioStent assets by Xenogenics Corporation from investment funds managed by Western Technology Investment and Silicon Valley Bank. Xenogenics Corporation also entered into a worldwide exclusive license with Rutgers University for rights to certain intellectual property related to the Ideal™ BioStent.
› Verified 2 days ago
| Entity Name | Ucp Physicians Of Central Texas, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922289412 PECOS PAC ID: 3173697935 Enrollment ID: O20080729000203 |
News Archive
An unexpected finding by an international team of scientists based at The University of Manchester and National Institutes of Health in America has shed new light on how immune cells are programmed to either repair or protect the body.
Drs. Andrew Goldstein, Owen Witte, and Tanya Stoyanova and their colleagues from UCLA's Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research have found that prostate cancer can develop in one type of stem cell, then evolve to be maintained by a stem cell that looks very different, making prostate cancer stem cells a "moving target" for treatments. The breakthrough discovery connects directly to the development of future therapeutics that target cancer and was published online ahead of print in the Proceedings of the National Academy of Sciences.
Frequent soccer ball heading is a common and under recognized cause of concussion symptoms, according to a study of amateur players led by Albert Einstein College of Medicine researchers.
Starting statin therapy as young as age 8 safely and effectively delays the early artery damage caused by familial hypercholesterolemia (FH), according to a Dutch study reported in the Aug.7th print issue of Circulation: Journal of the American Heart Association.
MultiCell Technologies, Inc. and its majority owned subsidiary, Xenogenics Corporation, are pleased to announce the acquisition of the Ideal™ BioStent assets by Xenogenics Corporation from investment funds managed by Western Technology Investment and Silicon Valley Bank. Xenogenics Corporation also entered into a worldwide exclusive license with Rutgers University for rights to certain intellectual property related to the Ideal™ BioStent.
› Verified 2 days ago
| Entity Name | Nextcare Primary Care Tx Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760875025 PECOS PAC ID: 0840501508 Enrollment ID: O20150622001791 |
News Archive
An unexpected finding by an international team of scientists based at The University of Manchester and National Institutes of Health in America has shed new light on how immune cells are programmed to either repair or protect the body.
Drs. Andrew Goldstein, Owen Witte, and Tanya Stoyanova and their colleagues from UCLA's Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research have found that prostate cancer can develop in one type of stem cell, then evolve to be maintained by a stem cell that looks very different, making prostate cancer stem cells a "moving target" for treatments. The breakthrough discovery connects directly to the development of future therapeutics that target cancer and was published online ahead of print in the Proceedings of the National Academy of Sciences.
Frequent soccer ball heading is a common and under recognized cause of concussion symptoms, according to a study of amateur players led by Albert Einstein College of Medicine researchers.
Starting statin therapy as young as age 8 safely and effectively delays the early artery damage caused by familial hypercholesterolemia (FH), according to a Dutch study reported in the Aug.7th print issue of Circulation: Journal of the American Heart Association.
MultiCell Technologies, Inc. and its majority owned subsidiary, Xenogenics Corporation, are pleased to announce the acquisition of the Ideal™ BioStent assets by Xenogenics Corporation from investment funds managed by Western Technology Investment and Silicon Valley Bank. Xenogenics Corporation also entered into a worldwide exclusive license with Rutgers University for rights to certain intellectual property related to the Ideal™ BioStent.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Matthew Scott Hamm, MD, MPH 72d Medical Group/sghq, 7050 Air Depot Blvd., Tinker Afb, OK 73145 Ph: (405) 582-6052 | Dr Matthew Scott Hamm, MD, MPH 16205 N Pennsylvania Ave, Edmond, OK 73013-7325 Ph: (405) 705-5700 |
News Archive
An unexpected finding by an international team of scientists based at The University of Manchester and National Institutes of Health in America has shed new light on how immune cells are programmed to either repair or protect the body.
Drs. Andrew Goldstein, Owen Witte, and Tanya Stoyanova and their colleagues from UCLA's Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research have found that prostate cancer can develop in one type of stem cell, then evolve to be maintained by a stem cell that looks very different, making prostate cancer stem cells a "moving target" for treatments. The breakthrough discovery connects directly to the development of future therapeutics that target cancer and was published online ahead of print in the Proceedings of the National Academy of Sciences.
Frequent soccer ball heading is a common and under recognized cause of concussion symptoms, according to a study of amateur players led by Albert Einstein College of Medicine researchers.
Starting statin therapy as young as age 8 safely and effectively delays the early artery damage caused by familial hypercholesterolemia (FH), according to a Dutch study reported in the Aug.7th print issue of Circulation: Journal of the American Heart Association.
MultiCell Technologies, Inc. and its majority owned subsidiary, Xenogenics Corporation, are pleased to announce the acquisition of the Ideal™ BioStent assets by Xenogenics Corporation from investment funds managed by Western Technology Investment and Silicon Valley Bank. Xenogenics Corporation also entered into a worldwide exclusive license with Rutgers University for rights to certain intellectual property related to the Ideal™ BioStent.
› Verified 2 days ago